Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib (SHR0302) in moderate to severe active rheumatoid arthritis
NCT03254966Phase 2Completed
- Sponsor
- Hengrui
- Start
- Nov 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ivarmacitinib in rheumatoid arthritis (RA) (5 arms), sponsored by Hengrui. Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Nov 2017; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03254966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254966.